Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:JNP

Juniper Pharmaceuticals (JNP) Stock Price, News & Analysis

Juniper Pharmaceuticals logo

About Juniper Pharmaceuticals Stock (NASDAQ:JNP)

Key Stats

Today's Range
$11.45
$11.50
50-Day Range
N/A
52-Week Range
$4.30
$13.25
Volume
28,513 shs
Average Volume
155,873 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Juniper Pharmaceuticals, Inc., a diversified healthcare company, focuses on developing novel intra-vaginal therapeutics that address unmet medical needs in women's health. It operates in two segments, Product and Service. The company develops its products utilizing its proprietary drug delivery technologies, which include bioadhesive delivery system, a polymer designed to adhere to epithelial surfaces or mucosa to achieve sustained and controlled delivery of active drug product; and a novel intravaginal ring technology. Juniper Pharmaceuticals, Inc. markets Crinone, a progesterone bioadhesive vaginal gel for progesterone supplementation or replacement as part of an assisted reproductive technology treatment for infertile women with progesterone deficiency. Its product candidates include JNP-0101, which is designed to deliver oxybutynin for the treatment of overactive bladder in women; JNP-0201, which contains natural progesterone and estradiol to be used for hormone replacement therapy in menopausal women; and JNP-0301, a natural progesterone for the prevention of preterm birth in women with a short cervical length. The company offers pharmaceutical product development; clinical trial manufacturing; and analytical and consulting services. Juniper Pharmaceuticals, Inc. has collaboration agreements with Merck KGaA and Allergan, as well as patent license agreement with Massachusetts General Hospital. The company was formerly known as Columbia Laboratories, Inc. and changed its name to Juniper Pharmaceuticals, Inc. in April 2015. Juniper Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Boston, Massachusetts.

Receive JNP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Juniper Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

JNP Stock News Headlines

Blackrock’s Sending THIS Crypto Higher on Purpose
It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…
See More Headlines

JNP Stock Analysis - Frequently Asked Questions

Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) posted its quarterly earnings results on Thursday, August, 9th. The specialty pharmaceutical company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of $0.04 by $0.18. The specialty pharmaceutical company earned $15.31 million during the quarter, compared to analyst estimates of $16.30 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that Juniper Pharmaceuticals investors own include Novavax (NVAX), Bristol-Myers Squibb (BMY), Verastem (VSTM), Madrigal Pharmaceuticals (MDGL), Merck & Co., Inc. (MRK), Rigel Pharmaceuticals (RIGL) and Synergy Pharmaceuticals (SGYP).

Company Calendar

Last Earnings
8/09/2018
Today
11/21/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:JNP
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Optionable
Beta
N/A
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

This page (NASDAQ:JNP) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners